Meredith Cook, who serves as senior vice president, general counsel and secretary at ANI Pharmaceuticals Inc. (NASDAQ: ANIP), completed a sale of 500 shares of the company's common stock on March 13, 2026, at $72.62 per share. The total value of the transaction was $36,310.
Following the trade, Cook directly holds 79,390 shares of ANI Pharmaceuticals. The sale was carried out under an existing Rule 10b5-1 trading plan that Cook adopted on September 15, 2025.
Company fundamentals and recent results
ANI is assigned a "GREAT" financial health score by the referenced metric in the report. Analysts covering the company project earnings of $9.40 per share for fiscal 2026.
Separately, ANI Pharmaceuticals reported fourth-quarter 2025 results that surpassed expectations. The company posted earnings per share of $2.33, topping forecasts of $1.97 and representing an 18.27% surprise in EPS. Revenue for the quarter came in at $247.1 million, ahead of projections of $232.37 million.
Despite the stronger-than-expected financial results, the company's stock showed a premarket decline following the release.
Research coverage
The company is listed among more than 1,400 U.S. equities included in comprehensive Pro Research Reports available on InvestingPro, as noted in the reporting material.
Contextual note
The sale of 500 shares by a senior officer was executed under an established 10b5-1 plan and left Cook with a substantial direct holding. ANI's most recent quarter outperformed analyst expectations on both EPS and revenue, although the market reaction in premarket trading was negative. Analysts' forward-looking EPS estimate for fiscal 2026 and the firm's financial health score are included in the published information.
The information presented here reflects the details disclosed regarding the transaction, ownership, trading plan, recent quarterly performance and analyst projections.